Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
Вставка
- Опубліковано 9 тра 2016
- With a new CEO at the helm, is it possible that Valeant can turn itself around or is the whole thing a value trap? Jim Cramer speaks to the new CEO to find out.
» Subscribe to CNBC: cnb.cx/SubscribeCNBC
» Watch more Mad Money here: bit.ly/WatchMadMoney
» Read more about Valeant here: cnb.cx/1WlBJUn
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: madmoney.cnbc.com
Watch full episodes: bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: bit.ly/LikeMadMoney
Follow Cramer on Twitter: bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: www.cnbc.com/
Find CNBC News on Facebook: cnb.cx/LikeCNBC
Follow CNBC News on Twitter: cnb.cx/FollowCNBC
Follow CNBC News on Google+: cnb.cx/PlusCNBC
Follow CNBC News on Instagram: cnb.cx/InstagramCNBC
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
haha "this is not about money". This dishonest CEO is a good fit to VRX values
lmfao
1:55 That is not Valeant's business model. It's a bad sign when the new CEO comes out the gate with spin so thick it would be classified as a lie by an objective observer. 2:55 Again, organic growth has not been their business model. For their sized company they have almost no R&D budget. They don't research, their model has been to buy drugs from other companies and then jack up the prices to ridiculous levels.
I think from this interview we know that Valeant's business model is dead as is the chance of that $200 share price again. This CEO confirmed that with Valeant's "focus" on pipeline now. The real question is if their new business can manage through the old business' debt which it likely can not since the old business was built on fast growth. The good news for patients is that some other company will buy the good products Valeant makes if the company ends up going under from its debt load.
It's kinda fun looking back on this video as Joe Papa has been executing his turn around plan to the T. Nice work Joe! Valeant will have a very bright future under hit leadership. Buy the stock while it's still cheap!!!!
Papa blew off the question about Valeant's using non-GAAP numbers. Cramer totally let him get away with it. And, then, in the end, Jim pretended like he had given a really hard-driving interview!! Sucks. Still, I am going to invest in Valeant, just on a hunch. :)
LIFE HAD SOME MELONCOLY FRIENDSHIPS THAT ALMOST COULD'VE HAPPENED--OLD JOE WAS SO SCARED WHEN HE SAW MOM IN THE HOME....
Dont forget the Apotec, Shermans murder. The said no to valeant.
Thats as shady as it gets
Buy the stock when it is cheap.
"Joe Papi"
Lmao